- Global biotechnology company focused on building innovative microbial platforms, Dyadic International ( NASDAQ: DYAI ) received ~$1.27M in connection with the sale of its equity interest in Alphazyme.
- The company received its equity as part of the consideration for the grant of a non-exclusive license to certain of Dyadic’s technology.
- The company also has the potential to receive additional payments based on the future sales of Alphazyme’s existing products.
- Stock trades 2% higher pre-market.
For further details see:
Dyadic rises 2%, sells equity interest in Alphazyme